November 25, 2022

Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study

  • Frank Kolligs,
  • Dirk Arnold,
  • Rita Golfieri,
  • ...
  • Niels de Jong,
  • Thomas Helmberger
  • on behalf of the CIRT Principal Investigators
Published online: November 25, 2022
100633

November 24, 2022

Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status

  • Mei-Hsuan Lee,
  • Ping-Feng Wu,
  • Tzu-I Chen,
  • ...
  • Hsuan-Yu Chen,
  • Yi-Tsung Lin,
  • Chien-Jen Chen
Published online: November 24, 2022
100634

November 21, 2022

Impact of waiting time on post-transplant survival for recipients with hepatocellular carcinoma: a natural experiment randomized by blood group

  • Berend R. Beumer,
  • Wojciech G. Polak,
  • Robert A. de Man,
  • ...
  • David van Klaveren,
  • Jeremy Labrecque,
  • Jan NM. IJzermans
Published online: November 21, 2022
100629

Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease

  • Jingjing Jiao,
  • Jessica I. Sanchez,
  • Omar Saldarriaga,
  • ...
  • Dipen M. Maru,
  • Heather L. Stevenson,
  • Laura Beretta
Published online: November 21, 2022
100628

November 15, 2022

Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency

  • Antonia Felzen,
  • Daan B.E. van Wessel,
  • Emmanuel Gonzales,
  • ...
  • Bettina E. Hansen,
  • Henkjan J. Verkade
  • the NAtural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) Consortium
Published online: November 15, 2022
100626

Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis

  • Lucilla Crudele,
  • Carlo De Matteis,
  • Elena Piccinin,
  • ...
  • Elsa Berardi,
  • Carlo Sabbà,
  • Antonio Moschetta
Published online: November 15, 2022
100627

November 6, 2022

Metabolic reprogramming of hepatocytes by Schistosoma mansoni eggs

  • Verena von Bülow,
  • Sarah Gindner,
  • Anne Baier,
  • ...
  • Christoph G. Grevelding,
  • Elke Roeb,
  • Martin Roderfeld
Published online: November 06, 2022
100625

November 3, 2022

November 1, 2022

Physical activity is inversely associated with hepatic fibro-inflammation: A population-based cohort study using UK Biobank data

  • Aron Sherry,
  • Scott A. Willis,
  • Thomas Yates,
  • ...
  • David J. Stensel,
  • Guruprasad P. Aithal,
  • James A. King
Published online: November 01, 2022
100622

October 28, 2022

Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis

  • Pei-Chang Lee,
  • Kuei-Chuan Lee,
  • Tsung-Chieh Yang,
  • ...
  • Bernd Schnabl,
  • Yi-Hsiang Huang,
  • Ming-Chih Hou
Published online: October 28, 2022
100619

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report

  • Jesús Rivera-Esteban,
  • Aurora Barberá,
  • Maria Teresa Salcedo,
  • Maria Martell,
  • Joan Genescà,
  • Juan M. Pericàs
Published online: October 28, 2022
100618

Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

  • Fabienne Marcellin,
  • Sylvie Brégigeon-Ronot,
  • Clémence Ramier,
  • ...
  • Virologie,
  • Data collection,
  • Management, statistical analyses
Published online: October 28, 2022
100614

October 27, 2022

Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis

  • Cheng-Hao Tseng,
  • Tzu-Haw Chen,
  • Jia-Ling Wu,
  • ...
  • Jaw-Town Lin,
  • Mindie H. Nguyen,
  • Yao-Chun Hsu
Published online: October 27, 2022
100617

Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity

  • Frederik T. Larsen,
  • Daniel Hansen,
  • Mike K. Terkelsen,
  • ...
  • Aleksander A. Krag,
  • Lars Grøntved,
  • Kim Ravnskjaer
Published online: October 27, 2022
100615

October 26, 2022

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

  • Bernhard Scheiner,
  • Daniel Roessler,
  • Samuel Phen,
  • ...
  • Enrico N. De Toni,
  • Lorenza Rimassa,
  • Matthias Pinter
Published online: October 26, 2022
100620

Does ammonia really disrupt brain oxygen homeostasis?

  • Michael Sørensen,
  • Hendrik Vilstrup
Published online: October 26, 2022
100616

October 12, 2022

A thermostable therapeutic vaccine is able to break immune tolerance in a mouse model of chronic hepatitis B

  • Julia Sacherl,
  • Anna D. Kosinska,
  • Kristina Kemter,
  • ...
  • Katrin Singethan,
  • Jens Altrichter,
  • Ulrike Protzer
Published online: October 12, 2022
100603

Histological and serological features of acute liver injury after SARS-CoV-2 vaccination

  • Greta Codoni,
  • Theresa Kirchner,
  • Bastian Engel,
  • ...
  • Yoh Zen,
  • Richard Taubert,
  • Benedetta Terziroli Beretta-Piccoli
Published online: October 12, 2022
100605

SCLY3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression

  • Martina Mang Leng Lei,
  • Carmen Oi Ning Leung,
  • Eunice Yuen Ting Lau,
  • ...
  • Irene Oi Lin Ng,
  • Stephanie Ma,
  • Terence Kin Wah Lee
Published online: October 12, 2022
100604

October 3, 2022

Social support and risk of mortality in liver cirrhosis: A cohort study

  • Gro Askgaard,
  • Lone Galmstrup Madsen,
  • Natasja von Wowern,
  • ...
  • Colin Crooks,
  • Joe West,
  • Peter Jepsen
Published online: October 03, 2022
100600

September 21, 2022

Patient-reported outcomes in NAFLD/NASH clinical trials: a blind spot that needs addressing

  • Elena Sena,
  • Ramiro Manzano-Nunez,
  • Jesus Rivera-Esteban,
  • Juan M. Pericas
Published online: September 21, 2022
100597

Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice

  • Jeffrey V. Lazarus,
  • Laurent Castera,
  • Henry E. Mark,
  • ...
  • Zobair M. Younossi,
  • Sven Francque,
  • Emmanuel A. Tsochatzis
Published online: September 21, 2022
100596

August 22, 2022

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

  • Stephen A. Harrison,
  • Peter J. Ruane,
  • Bradley Freilich,
  • ...
  • Timothy Rolph,
  • Andrew Cheng,
  • Kitty Yale
Published online: August 22, 2022
100563
Advertisement